FDA Warns Tissue Makers: Watch for Sepsis and TB Sneaks
Published Date: 2/3/2025
Notice
Summary
The FDA updated its guidance for companies handling human cells and tissues to better prevent the spread of sepsis and tuberculosis. These changes affect anyone who makes or uses these products, giving them new timelines to follow safety steps. This helps keep patients safer without adding big costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Guidance to Reduce Sepsis and TB Transmission
FDA issued revised guidances that provide recommendations to establishments that make donor eligibility determinations to reduce the risk of transmission of disease agents associated with sepsis and to screen donors for Mycobacterium tuberculosis (Mtb). The guidances are intended to help reduce infection risk for donors and recipients of human cells, tissues, and cellular and tissue-based products.
Implementation Deadline Extended to May 4, 2025
FDA changed the recommended compliance timeline for two HCT/P guidances. The guidances originally (published January 7, 2025) recommended implementation "as soon as feasible, but not later than 4 weeks after the guidance issue date," and FDA now recommends implementation by May 4, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2025-02154, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Labeling Requirements for Prescription Drugs
The FDA is updating its paperwork rules for prescription drug labels to keep things clear and safe. Drug makers must follow specific label info and can ask for exceptions, like barcode waivers or special rules for emergency stockpile products. Comments on these changes are open until March 5, 2025, so get your thoughts in before then!
Next: 2025-02168, Agency Information Collection Activities: Submission for OMB Review; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your feedback on their plan to collect info from the public. This is part of a routine check to make sure the info they gather is useful and not too much work for anyone. If you have thoughts, you’ve got until March 5, 2025, to share them—helping keep things clear and easy for everyone involved!